Conv. Plasma
Nigella Sativa

Home COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Andrographis paniculata for COVID-19

Andrographis paniculata has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Ningrum et al., Potency Of Andrographolide, L-Mimosine And Asiaticoside Compound As Antiviral For Covid-19 Based On In Silico Method, Proceedings Universitas Muhammadiyah Yogyakarta Undergraduate Conference, doi:10.18196/umygrace.v2i2.418
Introduction - COVID-19 is an infectious disease that is a global challenge, making it necessary for innovation and the development of antiviral agents in prevention and treatment efforts. Indonesia is known as a country rich in potential plants as medicine, a potential antiviral plant among them Andrographis paniculata , Mimosa pudica and Centella asiatica. The compound that have antiviral activity in each of these plants are andrographolide (Andrographis paniculata), L-mimosine (Mimosa pudica) and asiaticoside (Centella asiatica). The purpose of this study is to identify the potential of the andrographolide, l-mimosine and asiaticoside to inhibit SARS COV-2 protein and to predict the molecular drug profile which refers to lipinski's rule of 5.
 Purpose - The purpose of this study was to determine the potential of Andrographis paniculata , Mimosa pudica and Centella asiatica compounds in inhibiting the SARS CoV-2 protein and to determine the prediction of drug profiles such as molecules referring to Lipinski's rule of 5.
 Methodology - The methods used in this research by molecular docking and lipinski's Ro5 using PKCSM. The control compounds used are favipiravir and remdesivir.
 Results - The results of the affinity of target protein bonds using molecular docking obtained the best results in NSP3 proteins with An Asiaticoside docking score of -10.1 kcal / mol stronger than favipiravir -5.3 kcal/mol and remdesivir -8.6 kcal/mol. As for the compounds L-mimosine -6.1 kcal / mol and Andrographolide -7.7 kcal / mol. The compounds of andrographolide and L-mimosine showed good results and met the 5 aspects of Lipinski's Ro5, but asiaticoside compounds did not good enough. .
 Conclusion - The Research has concluded that the compound of the Andrographis paniculata , Mimosa pudica and Centella asiatica have a good potential in inhibiting SARS cov2 protein that is stronger than favipiravir and almost the same with remdesivir activity.
Ferreira et al., Potencialidades e riscos de espécies vegetais empregadas na terapêutica e/ou prevenção da COVID-19: revisão integrativa, OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA, doi:10.55905/oelv22n5-042
Desde o início da pandemia do novo coronavírus, houve grande preocupação diante de uma doença cujos possíveis impactos e morbidade ainda eram desconhecidos, iniciando, assim, uma corrida na descoberta de um tratamento para esta doença. Nesse sentido diversas pesquisas foram e estão sendo realizadas em busca de espécies vegetais passíveis de serem utilizadas na terapêutica da COVID-19. Portanto, esse estudo tem como objetivo realizar revisão de estudos etnodirigidos de espécies vegetais referenciadas na terapêutica e/ou prevenção da COVID-19. Foi realizada uma busca nas bases Scielo, LILACS e PubMed entre 2020 a 2022. Foram selecionados 32 artigos, predominando os de língua inglesa (n= 30), em 2021 (56,25%) e nos países Irã, Índia e Estados Unidos (15,62%); 86 espécies vegetais foram referidas, pertencentes a 51 famílias, com predomínio de Asteraceae e Laminaceae. As espécies mais referidas foram Glycyrrhiza glabra L. (4,65%) e Nigella sativa L. (3,48%), predominando o uso da raiz (29,4 %), preparadas como extrato aquoso (23,5%). Para futuros trabalhos, deve ser estimulada a continuidade dos estudos de validação com tais espécies, fundamentados na certificação de eficácia, segurança e qualidade; afim de minimizar os riscos do uso popular de produto inadequado e contribuir na pesquisa e desenvolvimento de um futuro bioproduto no tratamento do SARS-CoV-2.
Masoudi-Sobhanzadeh et al., Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries, Briefings in Bioinformatics, doi:10.1093/bib/bbab113
AbstractTo attain promising pharmacotherapies, researchers have applied drug repurposing (DR) techniques to discover the candidate medicines to combat the coronavirus disease 2019 (COVID-19) outbreak. Although many DR approaches have been introduced for treating different diseases, only structure-based DR (SBDR) methods can be employed as the first therapeutic option against the COVID-19 pandemic because they rely on the rudimentary information about the diseases such as the sequence of the severe acute respiratory syndrome coronavirus 2 genome. Hence, to try out new treatments for the disease, the first attempts have been made based on the SBDR methods which seem to be among the proper choices for discovering the potential medications against the emerging and re-emerging infectious diseases. Given the importance of SBDR approaches, in the present review, well-known SBDR methods are summarized, and their merits are investigated. Then, the databases and software applications, utilized for repurposing the drugs against COVID-19, are introduced. Besides, the identified drugs are categorized based on their targets. Finally, a comparison is made between the SBDR approaches and other DR methods, and some possible future directions are proposed.
Dofuor et al., The Global Impact of COVID-19: Historical Development, Molecular Characterization, Drug Discovery and Future Directions, Clinical Pathology, doi:10.1177/2632010x231218075
In December 2019, an outbreak of a respiratory disease called the coronavirus disease 2019 (COVID-19) caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China. The SARS-CoV-2, an encapsulated positive-stranded RNA virus, spread worldwide with disastrous consequences for people’s health, economies, and quality of life. The disease has had far-reaching impacts on society, including economic disruption, school closures, and increased stress and anxiety. It has also highlighted disparities in healthcare access and outcomes, with marginalized communities disproportionately affected by the SARS-CoV-2. The symptoms of COVID-19 range from mild to severe. There is presently no effective cure. Nevertheless, significant progress has been made in developing COVID-19 vaccine for different therapeutic targets. For instance, scientists developed multifold vaccine candidates shortly after the COVID-19 outbreak after Pfizer and AstraZeneca discovered the initial COVID-19 vaccines. These vaccines reduce disease spread, severity, and mortality. The addition of rapid diagnostics to microscopy for COVID-19 diagnosis has proven crucial. Our review provides a thorough overview of the historical development of COVID-19 and molecular and biochemical characterization of the SARS-CoV-2. We highlight the potential contributions from insect and plant sources as anti-SARS-CoV-2 and present directions for future research.
Yevsieieva et al., Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2, RSC Advances, doi:10.1039/d3ra06479d
The review outlines coronavirus SARS-CoV-2 morphology, life cycle, and essential proteins, focusing on a design strategy for dual-acting inhibitors for PLpro and Mpro proteases.
Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589
Despite the fact that coronavirus disease 2019 (COVID-19) treatment and management are now considerably regulated, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still one of the leading causes of death in 2022. The availability of COVID-19 vaccines, FDA-approved antivirals, and monoclonal antibodies in low-income countries still poses an issue to be addressed. Natural products, particularly traditional Chinese medicines (TCMs) and medicinal plant extracts (or their active component), have challenged the dominance of drug repurposing and synthetic compound libraries in COVID-19 therapeutics. Their abundant resources and excellent antiviral performance make natural products a relatively cheap and readily available alternative for COVID-19 therapeutics. Here, we deliberately review the anti-SARS-CoV-2 mechanisms of the natural products, their potency (pharmacological profiles), and application strategies for COVID-19 intervention. In light of their advantages, this review is intended to acknowledge the potential of natural products as COVID-19 therapeutic candidates.
Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622
The current coronavirus disease 2019 (COVID-19) outbreak is alarmingly escalating and raises challenges in finding efficient compounds for treatment. Repurposing phytochemicals in herbs is an ideal and economical approach for screening potential herbal components against COVID-19. Andrographis paniculata, also known as Chuan Xin Lian, has traditionally been used as an anti-inflammatory and antibacterial herb for centuries and has recently been classified as a promising herbal remedy for adjuvant therapy in treating respiratory diseases. This study aimed to screen Chuan Xin Lian’s bioactive components and elicit the potential pharmacological mechanisms and plausible pathways for treating COVID-19 using network pharmacology combined with molecular docking. The results found terpenoid (andrographolide) and flavonoid (luteolin, quercetin, kaempferol, and wogonin) derivatives had remarkable potential against COVID-19 and sequelae owing to their high degrees in the component-target-pathway network and strong binding capacities in docking scores. In addition, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that the PI3K-AKT signaling pathway might be the most vital molecular pathway in the pathophysiology of COVID-19 and long-term sequelae whereby therapeutic strategies can intervene.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.